Survival Contradiction in Stage II, IIIA, and IIIB Colon Cancer: A Surveillance, Epidemiology, and End Result-Based Analysis

2Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

There exists an inconsistency between stage and survival in the current American Joint Committee on Cancer (AJCC) staging system for colon cancer. In this study, we compared the clinicopathological characteristics and prognosis of colon cancer patients with stage II, IIIA, and IIIB disease based on the surveillance, epidemiology, and end results (SEER) database. Kaplan-Meier analysis was used to generate overall survival (OS) and cancer-specific survival (CSS) curves. The Cox regression was employed to identify risk factors. The competing risk model was completed by the cumulative incidence function and Gray's test. In the final population of 31,361 colon cancer patients, Kaplan-Meier curve analysis showed that stage IIIA had the highest OS and CSS, followed by stage IIA and IIIB, and IIB and IIC showed the worst OS and CSS. In the Cox model, the stage was proven to be an independent prognostic factor. In the competing risk model, stage IIIA colon cancer patients had the lowest 5-year cancer-specific death rate in stages II, IIIA, and IIIB. In conclusion, the prognosis of colon cancer patients in stage IIA was worse than that of patients in stage IIIA, while the survival rate of stage IIB and IIC was lower than that of stage IIIB.

Cite

CITATION STYLE

APA

Li, Y., Hua, R., He, J., & Zhang, H. (2022). Survival Contradiction in Stage II, IIIA, and IIIB Colon Cancer: A Surveillance, Epidemiology, and End Result-Based Analysis. Evidence-Based Complementary and Alternative Medicine, 2022. https://doi.org/10.1155/2022/4088117

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free